Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.

Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, Klasen S.

J Diabetes Complications. 2013 May-Jun;27(3):268-73. doi: 10.1016/j.jdiacomp.2012.11.005. Epub 2012 Dec 29.

PMID:
23276620
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A.

Diabetes Obes Metab. 2013 May;15(5):403-9. doi: 10.1111/dom.12038. Epub 2012 Dec 7.

PMID:
23163880
[PubMed - indexed for MEDLINE]
3.

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA.

Clin Ther. 2012 Aug;34(8):1761-71. doi: 10.1016/j.clinthera.2012.06.027. Epub 2012 Jul 15.

PMID:
22795925
[PubMed - indexed for MEDLINE]
4.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
[PubMed - indexed for MEDLINE]
5.

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ.

Diabetes Obes Metab. 2013 Aug;15(8):721-8. doi: 10.1111/dom.12081. Epub 2013 Mar 4.

PMID:
23398530
[PubMed - indexed for MEDLINE]
6.

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA.

Clin Drug Investig. 2011 Dec 1;31(12):839-51. doi: 10.2165/11594330-000000000-00000.

PMID:
21877761
[PubMed - indexed for MEDLINE]
7.

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ.

Diabetes Obes Metab. 2013 Jul;15(7):613-21. doi: 10.1111/dom.12073. Epub 2013 Feb 17.

PMID:
23356556
[PubMed - indexed for MEDLINE]
8.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group.

Diabetes Care. 2012 Jun;35(6):1232-8. doi: 10.2337/dc11-1926. Epub 2012 Apr 9.

PMID:
22492586
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.

Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G.

Int J Clin Pract. 2013 Dec;67(12):1267-82. doi: 10.1111/ijcp.12322. Epub 2013 Oct 13.

PMID:
24118688
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ.

Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185. Epub 2013 Aug 22.

PMID:
23906374
[PubMed - indexed for MEDLINE]
11.

[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].

Nauck M, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German.

PMID:
23529570
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.

Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K.

Hosp Pract (1995). 2013 Apr;41(2):72-84. doi: 10.3810/hp.2013.04.1020.

PMID:
23680739
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G.

Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.

PMID:
23850055
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G.

Diabetes Obes Metab. 2013 May;15(5):463-73. doi: 10.1111/dom.12090. Epub 2013 Mar 28.

PMID:
23464594
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Nicolle LE, Capuano G, Fung A, Usiskin K.

Postgrad Med. 2014 Jan;126(1):7-17. doi: 10.3810/pgm.2014.01.2720.

PMID:
24393747
[PubMed - indexed for MEDLINE]
16.

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators.

Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129.

PMID:
24007456
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.

Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H.

Diabetes Obes Metab. 2013 Dec;15(12):1136-45. doi: 10.1111/dom.12149. Epub 2013 Jul 14.

PMID:
23782594
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G.

Diabetes Obes Metab. 2013 Apr;15(4):372-82. doi: 10.1111/dom.12054. Epub 2013 Jan 24.

PMID:
23279307
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Studiengruppe Dapagliflozin 006.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S27-38. doi: 10.1055/s-0032-1305284. Epub 2013 Mar 25. German.

PMID:
23529568
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R.

Diabetes Obes Metab. 2013 Nov;15(11):1000-7. doi: 10.1111/dom.12121. Epub 2013 May 26.

PMID:
23627775
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk